World’s first lung cancer vaccine undergoing human trials – and it could change everything

World’s first lung cancer vaccine undergoing human trials – and it could change everything

Doctors have begun testing the world’s first mRNA lung cancer vaccine in seven countries.
The vaccine, named BNT116 and developed by BioNTech, targets non-small cell lung cancer (NSCLC)—the most common and deadly form of the disease.  Using the same mRNA technology as COVID-19 vaccines, this injection trains the immune system to recognize and destroy cancer cells while minimizing damage to healthy tissue.

Among the first participants is 67-year-old Janusz Rach from London, who began treatment at University College London Hospital (UCLH).
The phase 1 trial will include approximately 130 patients globally, including 20 in the UK, marking an important step toward making this type of therapy a treatment standard.

The vaccine is administered weekly, later transitioning to maintenance injections. It is combined with immunotherapy to enhance the body’s cancer-fighting defenses.  Researchers hope this revolutionary approach will not only treat existing tumors but also prevent recurrences – one of the biggest challenges in lung cancer survival.

If successful, future trial phases could usher in a new era of personalized cancer treatment and significantly improve outcomes for millions of patients worldwide.